{
    "paper_id": "0b93615eb9a5f66fc7b412af81f0893397305203",
    "metadata": {
        "title": "Supplementary Appendix",
        "authors": []
    },
    "abstract": [
        {
            "text": "This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Uriu K, Kimura I, Shirakawa K, et al. Neutralization of the SARS-CoV-2 mu variant by convalescent and vaccine serum. N Engl J Med.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "1 Table S1 . Number of Mu variant sequences isolated in each country. 5 Table S2 . Weekly new cases and numbers of different VOCs/VOIs in Colombia. 6 Table S3 . Haplotypes of the spike protein of Mu variant. 7 Table S4 . Mutations in the spike protein of Mu variant. 8 Table S5 . Mutations in the spike proteins of SARS-CoV-2 variants used in this study. 9 Table S6 . Summary of COVID-19 convalescent sera used in this study.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 2,
                    "end": 10,
                    "text": "Table S1",
                    "ref_id": "TABREF2"
                },
                {
                    "start": 72,
                    "end": 80,
                    "text": "Table S2",
                    "ref_id": null
                },
                {
                    "start": 150,
                    "end": 158,
                    "text": "Table S3",
                    "ref_id": null
                },
                {
                    "start": 210,
                    "end": 218,
                    "text": "Table S4",
                    "ref_id": "TABREF3"
                },
                {
                    "start": 269,
                    "end": 277,
                    "text": "Table S5",
                    "ref_id": null
                },
                {
                    "start": 357,
                    "end": 365,
                    "text": "Table S6",
                    "ref_id": "TABREF4"
                }
            ],
            "section": ""
        },
        {
            "text": "10 Table S7 . Summary of sera from BNT162b2-vaccinated individuals used in this study. 11 Table S8 . Primers used for the construction of Mu spike expression plasmid.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 3,
                    "end": 11,
                    "text": "Table S7",
                    "ref_id": null
                },
                {
                    "start": 90,
                    "end": 98,
                    "text": "Table S8",
                    "ref_id": "TABREF5"
                }
            ],
            "section": "Supplementary Appendix"
        },
        {
            "text": "12 Consortia 13",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Supplementary Appendix"
        },
        {
            "text": "were prepared in our previous studies. [3] [4] [5] A plasmid expressing the spike protein of the Mu (B.1.621) variant was generated by site-directed overlap extension PCR using pC-SARS2-S D614G 3 as the template and the primers listed in Table S8 . The resulting PCR fragment was digested with KpnI and NotI and inserted into the corresponding site of the pCAGGS vector. 6 Nucleotide sequences were determined by DNA sequencing services (Eurofins), and the sequence data were analyzed by Sequencher v5.1 software (Gene Codes Corporation).",
            "cite_spans": [
                {
                    "start": 39,
                    "end": 42,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 43,
                    "end": 46,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 47,
                    "end": 50,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 371,
                    "end": 372,
                    "text": "6",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [
                {
                    "start": 238,
                    "end": 246,
                    "text": "Table S8",
                    "ref_id": "TABREF5"
                }
            ],
            "section": "Supplementary Appendix"
        },
        {
            "text": "Pseudoviruses were prepared as previously described. [3] [4] [5] 7 Briefly, lentivirus (HIV-1)-based, luciferase-expressing reporter viruses were pseudotyped with the SARS-CoV-2 spikes. HEK293T cells (1 \u00d7 10 6 cells) were cotransfected with 1 \u03bcg psPAX2-IN/HiBiT, 8 1 \u03bcg pWPI-Luc2, 8 and 500 ng plasmids expressing parental S or its derivatives using PEI Max (Polysciences, Cat# 24765-1) according to the manufacturer's protocol. Two days post transfection, the culture supernatants were harvested and centrifuged. The pseudoviruses were stored at -80\u00b0C until use. Neutralization assays were performed as previously described. 4, 7 Briefly, the SARS-CoV-2 spike pseudoviruses (counting ~20,000 relative light units) were incubated with serially diluted (40-, 120-, 360-, 1,080-, 3,240-, 9,720-, and 29,160-fold dilution at the final concentration) heatinactivated human sera at 37\u00b0C for 1 h. Pseudoviruses without sera were included as controls. Then, an 80 \u03bcl mixture of pseudovirus and serum was added to HOS-ACE2/TMPRSS2 cells (10,000 cells/50 \u03bcl) in a 96-well white plate. Two days post infection, the infected cells were lysed with a One-Glo luciferase assay system (Promega, Cat# E6130), and the luminescent signal was measured using a GloMax explorer multimode microplate reader 3500 (Promega). The assay of each serum was performed in triplicate, and the 50% neutralization titer was calculated using Prism 9 (GraphPad Software). ",
            "cite_spans": [
                {
                    "start": 53,
                    "end": 56,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 57,
                    "end": 60,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 61,
                    "end": 64,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 65,
                    "end": 66,
                    "text": "7",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 263,
                    "end": 264,
                    "text": "8",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 281,
                    "end": 282,
                    "text": "8",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 626,
                    "end": 628,
                    "text": "4,",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 629,
                    "end": 630,
                    "text": "7",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Neutralization assay"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "An interactive web-based dashboard to track COVID-19 in real time",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Gardner",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Infect Dis",
            "volume": "20",
            "issn": "",
            "pages": "533--537",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "SARS-CoV-2 B.1.617 emergence and sensitivity to vaccineelicited antibodies",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Ferreira",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Datir",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kemp",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "BioRxiv",
            "volume": "2021",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ozono",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Ode",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Nat Commun",
            "volume": "12",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Kimura",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Kosugi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "BioRxiv",
            "volume": "2021",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Motozono",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Toyoda",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zahradnik",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Cell Host Microbe",
            "volume": "29",
            "issn": "",
            "pages": "1124--1160",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Efficient selection for high-expression transfectants with a novel eukaryotic vector",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Niwa",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Yamamura",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Miyazaki",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "Gene",
            "volume": "108",
            "issn": "",
            "pages": "193--202",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Saito",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Nasser",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Uriu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "BioRxiv",
            "volume": "2021",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide tag",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ozono",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tobiume",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kishigami",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Tokunaga",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Biol Chem",
            "volume": "295",
            "issn": "",
            "pages": "13023--13053",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Representative neutralization curves. 4",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Representative neutralization curves. Representative results of virus neutralization assays using four convalescent sera (donors 01-07, PS315, PS324 and PS362; top panel) and four BNT162b2-vaccinated sera (donors #020-3, #021-3, #045-3 and #056-3; bottom panel) are shown. The percentages of pseudovirus infectivity compared to that without sera are shown. Assays were performed in triplicate, and data are average with standard deviation. The number in each panel indicates the 50% neutralization titers of the respective serum. The fitting curve of parental virus of respective serum is shown as broken black lines in all panels. The 50% neutralization titers are summarized inTables S6 and S7.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Number of Mu variant sequences isolated in each country.Table S2. Weekly new cases and numbers of different VOCs/VOIs in Colombia.Table S3. Haplotypes of the spike protein of Mu variant.",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Mutations in the spike protein of Mu variant.",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "Summary of COVID-19 convalescent sera used in this study.",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "Primers used for the construction of Mu spike expression plasmid.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "We would like to thank all members of The Genotype to Phenotype Japan (G2P-Japan) Consortium. The super-computing resource was provided by the Human Genome Center at the University of Tokyo and the NIG supercomputer at ROIS National Institute of Genetics. We thank Dr. Kenzo Tokunaga (National Institute of Infectious Diseases, Japan) for sharing materials, Dr. Daniel Sauter (University Hospital T\u00fcbingen, Germany) and Dr. Yoshinori Fukazawa (Oregon Health & Science University, USA) for proofreading and helpful comments, and Dr. Pa\u00fal C\u00e1rdenas (Universidad San Francisco de Quito, Ecuador) for helpful suggestions.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Acknowledgments"
        }
    ]
}